ArticleJapanese journal of radiology2026
Conventional MRI/CT for differentiation of IDH-mutant adult-type diffuse gliomas: revisited with a new imaging feature "scFLAIR-D".
Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Imaging diagnosis of adult-type diffuse gliomas in the era of WHO CNS5 and cIMPACT-NOW updates 8-11: a narrative review.Japanese journal of radiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo test whether a refined definition of the T2-FLAIR mismatch sign (redefined T2FM) and a newly defined subcortical FLAIR signal drop (scFLAIR-D) on conventional MRI improve presurgical discrimination between astrocytoma, IDH-mutant (AST) and oligodendroglioma, IDH-mutant and 1p/19q-codeleted (ODG). MATERIALS AND
methodsIn this single-center retrospective study (January 2021-July 2025), adults with IDH-mutant adult-type diffuse glioma and preoperative T2-weighted and FLAIR MRI were included. Two blinded readers (with senior adjudication) scored five features: redefined T2FM (includes partial but excludes subcortical-only mismatch), scFLAIR-D (focal FLAIR hypointensity confined to subcortical white matter within T2-hyperintensity), multiple necrotic/cystic foci (≥ 2 cavities), cortical predominance (> 50% cortical volume), and calcification (CT).
resultsForty-one patients were included (median age 42 years; 24 men; 16 AST, 25 ODG). AST significantly more often showed redefined T2FM (AST: 87.5% [14/16] vs. ODG: 20.0% [5/25]; p < 0.001) than ODG. ODG significantly more often showed scFLAIR-D (AST: 6.3% [1/16] vs. ODG: 44.0% [11/25]; p = 0.013), multiple necrotic/cystic foci (12.5% [2/16] vs. 56.0% [14/25]; p = 0.008), and calcification (0% [0/16] vs. 50.0% [12/24 patients with preoperative CT]; p < 0.001); cortical predominance trended higher (31.3% [5/16] vs. 64.0% [16/25]; p = 0.058). For predicting AST, redefined T2FM achieved 87.5% sensitivity and 80.0% specificity. For predicting ODG, scFLAIR-D achieved 44.0% sensitivity and 93.8% specificity. Two or more ODG-favored features (scFLAIR-D, multiple necrotic/cystic foci, calcification) identified ODG with 100% specificity, whereas redefined T2FM without ODG-favored features identified AST with 96.0% specificity.
conclusionA refined T2FM definition improves sensitivity for AST while preserving high specificity. scFLAIR-D serves as a simple, specific marker of ODG; in combination, these routine features yield high rule-in specificity to support presurgical planning and early therapeutic counseling. Refining T2FM to include partial but exclude subcortical-only mismatch increased sensitivity for astrocytoma, IDH-mutant (87.5%) while preserving specificity (80.0%). Newly defined scFLAIR-D was highly specific for oligodendroglioma, IDH-mutant and 1p/19q-codeleted (93.8%). Combining these qualitative MRI/CT features yielded high rule-in specificities for lineage discrimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.